Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OxThera has been granted two new US patents and one new Australian patent during the last year.
Subscribe to our email newsletter
OxThera holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in eight patent families.
The newly granted US patents have numbers 8,486,389 and 8,545,836. The new Australian patent has number 2006326016.
"These patents will secure the pharmaceutical composition and the method for treating and preventing oxalate-related disease with micro-organisms and enzymes and further strengthen the Company’s patent estate and worldwide rights for the treatment of hyperoxaluria. "
"The US rights are important additions to our already granted patents in Europe and the US.
"Additionally, our lead product Oxabact is currently in a phase 2 trial and results of this clinical study are expected to be available this autumn," said Elisabeth Lindner, CEO of OxThera.
Oxabact is an oral product composed of highly concentrated live bacteria (Oxalobacter formigenes). The drug is designed for delivery in the small intestine, where enteric elimination of endogenous oxalate is initiated.
OxThera is currently pursuing a complete Oxabact clinical development program in the EU and in the US for the treatment of patients suffering from Primary Hyperoxaluria.
Oxazyme is an oral enzyme administered as an enterically-coated granulate. The product is designed to break down dietary oxalate in the upper GI tract. The product is developed to treat hyperoxaluria and kidney stones caused by excess intake of dietary oxalate.